MedPath

Study of BMS-275183 in Patients With Pre-treated Non-small Cell Lung Cancer

Phase 2
Terminated
Conditions
Non-small Cell Lung Cancer
Registration Number
NCT00099879
Lead Sponsor
Bristol-Myers Squibb
Brief Summary

The purpose of this clinical research study is to learn if BMS-275183 can shrink or slow the growth of the cancer in subjects with non-small cell lung cancer (NSCLC). The safety of this treatment will also be studied.

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  • Advanced or metastatic pretreated NSCLC
  • Measurable disease
  • Adequate hematologic, hepatic and renal functions
  • ECOG Performance Status of 0-2
Exclusion Criteria
  • Inability to swallow capsules
  • Recent significant cardiovascular disease
  • Woman who are pregnant or breastfeeding

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (2)

Local Insitution

🇳🇱

Groningen, Netherlands

Local Institution

🇬🇧

Manchester, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath